SNPMiner Trials (Home Page)
Report for Clinical Trial NCT00092391
Developed by Shray Alag, 2020-2021.
SNP Clinical Trial Gene
The purpose of this study is to determine the mumps virus strength at the end of shelf-life
(expiration date) of an approved vaccine.
NCT00092391 Measles Mumps Rubella Varicella
2 Interventions
Name: Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live
Description: 0.5 mL subcutaneous injection of one of three sub-lots on Day 0
Type: Biological
Group Labels: 3 Control Group Mumps Expiry Group 1 Mumps Expiry Group 2
Name: Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)
Description: 0.5 mL subcutaneous injection on Day 0
Type: Biological
Group Labels: 3 Control Group Mumps Expiry Group 1 Mumps Expiry Group 2
Primary Outcomes
Measure: Neutralizing antibodies to mumps at 6 weeks postvaccination Time: 6 weeks postvaccination
Secondary Outcomes
Measure: Geometric mean titers to mumps by ELISA at 6 weeks and at 1 year postvaccination Time: 6 weeks and 1 year postvaccination
Purpose: Prevention
Allocation: Randomized
Single Group Assignment
There is one SNP
SNPs
A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)
The purpose of this study is to determine the mumps virus strength at the end of shelf-life
(expiration date) of an approved vaccine. --- V205C ---